News
Filter By:
- All
- Blog
- In the News
- Press Releases
- Publications
- All
- Blog
- In the News
- Press Releases
- Publications
Dyno Therapeutics Named on the Forbes List of America’s Best Startup Employers 2022
BOSTON, MA — March 11, 2022— Dyno Therapeutics is pleased to announce it has been recognized on the Forbes list of America’s Best Startup Employers 2022. …
Hera – the missing Argo Workflows Python SDK
At Dyno, we believe in collective innovation on our journey of empowering a diverse team of the best problem solvers to drive cutting edge science …
Dyno Therapeutics at Goldman Sachs Byte-ology Conference
Discussing the Convergence of Biotechnology and Technology Boston, Dec. 9, 2021 – Dyno Therapeutics announced today that management is scheduled to participate at the Goldman …
Dyno Therapeutics Named Emerging Company of the Year at New England Venture Capital Association’s 2021 NEVY Awards
BOSTON, MA — December 6, 2021— Dyno Therapeutics has announced it was selected for the Emerging Company of the Year Award in the Life …
Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle
Dyno receives $18 million upfront and is eligible for milestone and royalty payments potentially exceeding $1.6 billion TOKYO and CAMBRIDGE, Mass., Dec. 2, 2021 – Astellas Pharma Inc. (TSE: …
Our Focus on Mission Driven Collective Innovation
Dyno empowers a diverse team of the best problem-solvers to drive cutting-edge science toward improving patient health. Our mission is to build the ideal capsid …
The Endpoints 11: They’ve got mad money and huge ambitions. It’s time to go big or go home
These days, selecting a group of private biotechs for the Endpoints 11 spotlight begins with a sprint to get ahead of IPOs and the M&A teams at Big Pharma.
Introduction to AAV as a Gene Therapy Vector, Part 2
What are AAVs? and what makes them good candidates for gene therapy? By: Christopher Reardon, Stephen Malina, and Eryney Marrogi Introduction In the first part …
Meet the 24 biotech startups that top VCs say are poised to take off in the next 12 months
Every day seems to bring a fundraising record and a new company launching in the biotech industry. Insider spoke with some of the smartest and most plugged-in venture capitalists in biotech to pinpoint the most exciting startups.
Introduction to AAV as a Gene Therapy Vector, Part 1
What are AAVs? and what makes them good candidates for gene therapy? By: Stephen Malina, Eryney Marrogi, and Christopher Reardon. In two previous posts, we …
Delivering an experience our AAViators expect through Agile work practices
At Dyno, we are empowering a diverse team of the best problem-solvers to drive cutting-edge science toward improving patient health. This is easy to say …
Dyno Therapeutics Presents State-of-the-Art Applications of Machine Learning to Design Improved AAV Capsids for a Broad Range of Gene Therapies at American Society of Gene and Cell Therapy Conference
Presentations describe use of in vivo screening and machine learning to accelerate the analysis, design, and validation of improved AAV vectors.
Dyno Therapeutics ASGCT After-Party
Please join us at the 2021 Dyno Therapeutics **ASGCT After-Party, May 13th** beginning at 7p!
Giant steps: Dyno closes $100M series A round for advanced capsid engineering
The allocation of capital to the build-out of next-generation gene therapies continues apace. Dyno Therapeutics Inc., a leader in applying artificial intelligence to advanced capsid engineering, raised $100 million in a series A round to fund its expansion and that of its Capsidmap platform.
Dyno raises $100 million to bring artificial intelligence to gene therapy
Dyno Therapeutics, a Cambridge biotech that uses artificial intelligence techniques to develop gene therapies, said Thursday that it has raised $100 million from investors.
